233 related articles for article (PubMed ID: 29144249)
1. Effect of Antiandrogen, Aromatase Inhibitor, and Gonadotropin-releasing Hormone Analog on Adult Height in Familial Male Precocious Puberty.
Leschek EW; Flor AC; Bryant JC; Jones JV; Barnes KM; Cutler GB
J Pediatr; 2017 Nov; 190():229-235. PubMed ID: 29144249
[TBL] [Abstract][Full Text] [Related]
2. Treatment of familial male precocious puberty with spironolactone, testolactone, and deslorelin.
Laue L; Jones J; Barnes KM; Cutler GB
J Clin Endocrinol Metab; 1993 Jan; 76(1):151-5. PubMed ID: 8421081
[TBL] [Abstract][Full Text] [Related]
3. Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin suppressive effect and final height obtained with two different analogs.
Lanes R; Soros A; Jakubowicz S
J Pediatr Endocrinol Metab; 2004 May; 17(5):759-66. PubMed ID: 15237711
[TBL] [Abstract][Full Text] [Related]
4. Factors determining normal adult height in girls with gonadotropin-dependent precocious puberty treated with depot gonadotropin-releasing hormone analogs.
Brito VN; Latronico AC; Cukier P; Teles MG; Silveira LF; Arnhold IJ; Mendonca BB
J Clin Endocrinol Metab; 2008 Jul; 93(7):2662-9. PubMed ID: 18460564
[TBL] [Abstract][Full Text] [Related]
5. Combined therapy with GnRH analog plus growth hormone in central precocious puberty.
Pucarelli I; Segni M; Ortore M; Moretti A; Iannaccone R; Pasquino AM
J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():811-20. PubMed ID: 10969926
[TBL] [Abstract][Full Text] [Related]
6. The effects of gonadotropin releasing hormone analogue therapy on girls with gonadotropin-dependent precocious puberty.
Tung YC; Lee JS; Tsai WY; Hsiao PH
J Formos Med Assoc; 2007 Oct; 106(10):826-31. PubMed ID: 17964961
[TBL] [Abstract][Full Text] [Related]
7. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function.
Pasquino AM; Pucarelli I; Accardo F; Demiraj V; Segni M; Di Nardo R
J Clin Endocrinol Metab; 2008 Jan; 93(1):190-5. PubMed ID: 17940112
[TBL] [Abstract][Full Text] [Related]
8. Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset.
Leschek EW; Jones J; Barnes KM; Hill SC; Cutler GB
J Clin Endocrinol Metab; 1999 Jan; 84(1):175-8. PubMed ID: 9920079
[TBL] [Abstract][Full Text] [Related]
9. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone.
Pasquino AM; Pucarelli I; Segni M; Matrunola M; Cerroni F
J Clin Endocrinol Metab; 1999 Feb; 84(2):449-52. PubMed ID: 10022399
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes after gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty.
Shim YS; Lim KI; Lee HS; Hwang JS
PLoS One; 2020; 15(12):e0243212. PubMed ID: 33301485
[TBL] [Abstract][Full Text] [Related]
11. Should Skeletal Maturation Be Manipulated for Extra Height Gain?
Wit JM
Front Endocrinol (Lausanne); 2021; 12():812196. PubMed ID: 34975773
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of anastrozole and cyproterone acetate in two brothers with familial male precocious puberty.
Eyssette-Guerreau S; Pinto G; Sultan A; Le Merrer M; Sultan C; Polak M
J Pediatr Endocrinol Metab; 2008 Oct; 21(10):995-1002. PubMed ID: 19209621
[TBL] [Abstract][Full Text] [Related]
13. Adult height in patients with familial male-limited precocious puberty and the role of an aromatase inhibitor in patient management.
Lane LC; Flowers J; Johnstone H; Cheetham T
J Pediatr Endocrinol Metab; 2018 Apr; 31(5):551-560. PubMed ID: 29654692
[TBL] [Abstract][Full Text] [Related]
14. Treatment of familial male precocious puberty with spironolactone and testolactone.
Laue L; Kenigsberg D; Pescovitz OH; Hench KD; Barnes KM; Loriaux DL; Cutler GB
N Engl J Med; 1989 Feb; 320(8):496-502. PubMed ID: 2492636
[TBL] [Abstract][Full Text] [Related]
15. Anastrozole plus leuprorelin in early maturing girls with compromised growth: the "GAIL" study.
Papadimitriou DT; Dermitzaki E; Papagianni M; Papaioannou G; Papaevangelou V; Papadimitriou A
J Endocrinol Invest; 2016 Apr; 39(4):439-46. PubMed ID: 26507391
[TBL] [Abstract][Full Text] [Related]
16. Effects of combined gonadotropin-releasing hormone agonist and growth hormone therapy on adult height in precocious puberty: a further contribution.
Pucarelli I; Segni M; Ortore M; Arcadi E; Pasquino AM
J Pediatr Endocrinol Metab; 2003 Sep; 16(7):1005-10. PubMed ID: 14513877
[TBL] [Abstract][Full Text] [Related]
17. Testotoxicosis: current viewpoint.
Reiter EO; Norjavaara E
Pediatr Endocrinol Rev; 2005 Dec; 3(2):77-86. PubMed ID: 16361981
[TBL] [Abstract][Full Text] [Related]
18. Bicalutamide and third-generation aromatase inhibitors in testotoxicosis.
Lenz AM; Shulman D; Eugster EA; Rahhal S; Fuqua JS; Pescovitz OH; Lewis KA
Pediatrics; 2010 Sep; 126(3):e728-33. PubMed ID: 20713483
[TBL] [Abstract][Full Text] [Related]
19. Height prognosis of children with true precocious puberty and growth hormone deficiency: effect of combination therapy with gonadotropin releasing hormone agonist and growth hormone.
Cara JF; Kreiter ML; Rosenfield RL
J Pediatr; 1992 May; 120(5):709-15. PubMed ID: 1533661
[TBL] [Abstract][Full Text] [Related]
20. Adult height, body mass index and time of menarche of girls with idiopathic central precocious puberty after gonadotropin-releasing hormone analogue treatment.
Poomthavorn P; Suphasit R; Mahachoklertwattana P
Gynecol Endocrinol; 2011 Aug; 27(8):524-8. PubMed ID: 21501002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
